Skip to Content

Notice

Government-Owned Inventions; Availability for Licensing

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

National Institutes of Health, Public Health Service, HHS.

ACTION:

Notice.

SUMMARY:

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES:

Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Antibodies That Specifically Recognize S100A15, a Protein Involved in Epidermal Differentiation and Inflammation

Description of Technology: This technology describes rabbit polyclonal antibodies that recognize the human and mouse S100A15 proteins. S100A15 is involved in epidermal differentiation Start Printed Page 30429and inflammation, and is dysregulated in skin tumors and inflammatory psoriasis.

Applications: Diagnostic tool for evaluation of agents that alter skin pathology; research tool to probe the role of S100A15 during epidermal maturation, skin carcinogenesis, and inflammation; diagnostic tool for the clinical evaluation of skin tumors and inflammatory diseases such as psoriasis.

Development Status: Early stage.

Inventors: Ronald Wolf, Stuart H. Yuspa, Paul Goldsmith, and Christopher J. Voscopoulos (NCI).

Publication: R. Wolf et al., “The mouse S100A15 ortholog parallels genomic organization, structure, gene expression, and protein-processing pattern of the human S100A7/A15 subfamily during epidermal maturation,” J Invest Dermatol advance online publication 09 March 2006, doi: 10.1038/sj.jid.5700210.

Patent Status: HHS Reference No. E-145-2006/0—Research Tool.

Licensing Status: Available for non-exclusive licensing under a Biological Materials License.

Licensing Contact: Marlene K. Astor, JD, MS, MIP; 301/435-4426; ms482m@nih.gov.

Potent Pharmacophoric Delta- and Mu-Opioid Receptor Antagonists and Conversion of Endomorphin Mu-Opioid Agonists to Antagonists

Description of Technology: The inhibition (antagonism) of mu-opioid receptors is a critical human health topic, since this receptor is the key element in the neural reward pathway in the central nervous system responsible for craving and addiction to food, alcohol or various drugs, such as morphine and its derivatives. Furthermore, antagonists to these receptors are absent in nature. This invention provides compositions for new modified opioid antagonists.

For example, a series of dimeric N,N-dimethyl-Dmt-Tic (2',6'-dimethyl-l-tyrosyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) analogues were covalently linked tail-to-tail through diaminoalkane, and symmetric or asymmetric 3,6-diaminoalkyl-2(1 H)-pyrazinone moieties. The latter compounds exhibit dual antagonism toward delta- and mu-opioid receptors providing a means to simultaneously regulate two independent opioid receptors to combat addiction, tolerance, and alcohol dependency. Dmt is the essential pluripotent amino acid residue that regulates binding to all opioid receptor molecules, which are classified into delta, mu, and kappa subtypes depending on the type of interacting opioid. Compounds from another class of mu-opioid antagonists were also prepared, including [N-allyl-Dmt1]endomorphin-1 (N-allyl-Dmt-Pro-Trp-Phe-NH2) and [N-allyl-Dmt1]endomorphin-2 (N-allyl-Dmt-Pro-Phe-Phe-NH2).

The former set of dimeric compounds readily pass through the epithelial barriers in the gut and brain when injected systematically or taken orally. Additionally, these bivalent ligands would be attractive in drug design due to their stability to proteolytic degradation. That they are also slightly more hydrophobic may increase potency by their ability to transit membranes.

Application: Potential opiate, food and alcohol addiction therapeutics.

Development Status: Early stage.

Inventors: Lawrence H. Lazarus (NIEHS) et al.

Publications:

T Li et al., “Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists,” (2005) J Med Chem. 48:8035-44.

T Li et al., “New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif,” (2005) Bioorg Med Chem Lett. 15:5517-20.

Patent Status: U.S. Provisional Application No. 60/714,071 filed 04 Feb 2005 (HHS Reference No. E-305-2005/0-US-01).

Licensing Status: This technology is available for exclusive, co-exclusive, or nonexclusive licensing.

Licensing Contact: Marlene K. Astor, JD, MS, MIP; 301/435-4426; ms482m@nih.gov.

Collaborative Research Opportunity: The National Institute of Environmental Health Sciences, Laboratory of Pharmacology and Chemistry, Medicinal Chemistry Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John S. Penta, PhD. at 919-541-3696 or penta@niehs.nih.gov for more information.

Novel Glycated Peptides and Proteins as Biomarkers for Diabetes Control

Description of Technology: A primary goal of diabetes therapy is to improve control of blood glucose levels (known as glycemic control) in patients. Prospective studies of both Type 1 and Type 2 diabetes indicate that careful glycemic control significantly reduces the risk of microvascular, neurological, and cardiovascular complications of diabetes.

The current method to monitor glycemic control is by measurement of the relative concentration of glycated red-cell hemoglobin (HbA1C). However, levels of HbA1C, an intracellular protein, reflect glycemic control over a timeframe of several months. They are also susceptible to a variety of perturbing factors such as hematologic disorders, kidney disease, aspirin or penicillin use, or alcohol intake.

This technology describes a family of novel glycated peptide and protein biomarkers for glycemic control, as well as a method to monitor glycemic control in diabetic patients. In contrast to HbA1C, which is an intracellular protein, the glycated proteins described in this invention are found in blood plasma, and might reflect changes in glycemic control more rapidly, and with more sensitivity. A test developed using this technology could be envisioned to supplement or replace current monitoring of glycemic control by HbA1C. Also described are methods for making antibodies and aptamers that bind the described glycated peptides and proteins, and a database listing glycated peptide concentrations in diabetic and control samples.

Applications: Diagnostic tool to monitor glycemic control in diabetic or at-risk individuals; markers to track development of diabetes complications.

Development Status: Early stage.

Inventors: Perry J. Blackshear (NIEHS).

Patent Status: U.S. Provisional Application No. 60/779,710 filed 06 Mar 2006 (HHS Reference No. E-057-2005/0-US-01).

Licensing Status: This technology is available for exclusive, co-exclusive, or nonexclusive licensing.

Licensing Contact: Marlene K. Astor, JD, MS, MIP; 301/435-4426; ms482m@nih.gov.

Collaborative Research Opportunity: The National Institute of Environmental Health Sciences, Office of Clinical Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John S. Penta, PhD. at 919-541-3696 or penta@niehs.nih.gov for more information.

Start Signature

Dated: May 18, 2006.

David R. Sadowski,

Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

End Signature End Preamble

[FR Doc. E6-8168 Filed 5-25-06; 8:45 am]

BILLING CODE 4140-01-P